Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Original Article
Evaluation of hospital admissions in the first 6 months after the COVID-19 discharge
Aims: Although COVID-19 disease has many effects on patients after recovery, it is not known whether these effects are part of the recovery process or trigger other diseases. This study has aimed to investigate whether ferritin, which is used as an acute phase reactant to determine the severity and prognosis of the disease, has a role in determining the symptoms that occur after the disease.
Methods: The study was conducted with 300 patients who were hospitalized with PCR positive and lung involvement. Patients' hospital admissions and initial ferritin levels were recorded within 6 months of discharge. It was examined whether there was a relationship between ferritin levels and the re-admission reasons.
Results: 177(59.0) people had no symptoms during the six-month period and 123(41.0) patients were admitted to the hospital due to various symptoms. 6(2.0) of the patients became ex within six months after discharge. The most common symptoms in patients were 28(9.3) shortness of breath, 22(7.3) myalgia, 15(5.0) chest pain, 10(3.3) headache and 10(3.3) palpitations, respectively. Ferritin levels were found to be high in those with no symptoms and low in those with symptoms.
Conclusion: Determining the symptoms, re-admissions, mortality rates and predictors that will guide Covid -19 is very important for the recognition, treatment and follow-up of this disease after discharge. More studies are needed to make a prediction according to ferritin levels in the process after recovery from Covid-19.

1. Carfì A, Bernabei R, Landi F, Gemelli against COVID-19 Post-acute CareStudy Group. Persistent symptoms in patients after acute COVID-19.JAMA. 2020;324:603-605.
2. Lamprecht, B. Gibt es ein post-COVID-Syndrom? Der Pneumol.2020;17:398-405.
3. National Institutes of Health (NIH). NIH launches new initiative to study “Long COVID.” https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid(Accessed on February 26, 2021).
4. Rubin R. As their numbers grow, COVID-19 “long haulers” stumpexperts. JAMA. 2020;324(14):1381-1383.
5. Goërtz YM, Van Herck M, Delbressine JM, et al. Persistent symptoms 3months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?.ERJ Open Res. 2020;6(4):00542-2020.
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality ofadult inpatients with COVID-19 in Wuhan, China: a retrospective cohortstudy. Lancet. 2020;395:1054-1062.
7. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. IntImmunol. 2017;29:401-409. https://doi.org/10.1093/intimm/ dxx031
8. Patel A, Jernigan DB, 2019-nCoV CDC Response Team. Initial PublicHealth Response and Interim Clinical Guidelines for the 2019 NovelCoronavirus Outbreak - United States, 31 Dec 2019 - 4 Feb 2020. MMWRMorb Mortal Wkly Rep. 2020;69:140.
9. Evaluating and Caring for Patients with Post-COVID Conditions:InterimGuidance https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html (Accessed on June 15, 2021).
10. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors inWuhan, China: a single-centre longitudinal study. Clin Microbiol Infect.2021;27(1):89-95.
11. Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-dayoutcomes among patients hospitalized with COVID-19. Ann Intern Med.2021;174(4):576.
12. Bowles KH, McDonald M, Barrón Y, Kennedy E, O’Connor M, MikkelsenM. Surviving COVID-19 after hospital discharge: symptom, functional,and adverse outcomes of home health recipients. Ann Intern Med.2021;174(3):316.
13. Lavery AM, Preston LE, Ko JY, et al. Characteristics of hospitalizedCOVID-19 patients discharged and experiencing same-hospitalreadmission - United States, March-August 2020. Morb Mortal Wkly Rep.2020;69(45):1695.
14. Ayoubkhani D, Khunti K, Nafilyan V, et al Post-covid syndrome inindividuals admitted to hospital with COVID-19: retrospective cohortstudy. BMJ. 2021;372:n693. doi:10.1136/bmj.n693
15. Iaccarino G, Grassi G, Borghi C, et al. SARS-RAS investigators. age andmultimorbidity predict death among COVID-19 patients: results of theSARS-RAS study of the Italian society of hypertension. Hypertension.2020;76(2):366-372.
16. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortalitydue to COVID-19 based on an analysis of data of 150 patients fromWuhan. China Intensive Care Med. 2020;46(5):846-848.
17. Mehta P, McAuley DF, Brown M, et al. HLH Across SpecialityCollaboration, UK. COVID-19: consider cytokine storm syndromes andimmunosuppression. Lancet. 2020;395(10229):1033-1034.
18. Bennett TD, Hayward KN, Farris RW, Ringold S, Wallace CA, Brogan TV.Very high serum ferritin levels are associated with increased mortality andcritical care in pediatric patients. Pediatr Crit Care Med. 2011;12:e233-236. https://doi.org/10.1097/ PCC.0b013e31820abca8
19. Carcillo JA, Sward K, Halstead ES, et al. A systemic inflammation mortalityrisk assessment contingency table for severe sepsis. Pediatr Crit Care Med.2017;18:143-150. https://doi.org/10.1097/ pcc.0000000000001029
20. Carubbi F, Salvati L, Alunno A, et al. Ferritin is associated with theseverity of lung involvement but not with worse prognosis in patientswith COVID-19:data from two Italian COVID-19 units. Scientific Reports.2020;11, 4863.
Volume 3, Issue 2, 2023
Page : 100-103